Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEAM trial of bortezomib with high-dose cytarabine and gemtuzumab ozogamicin in relapsed/refractory AML
2017-005158-12Phase 2Completed
- Sponsor
- Heidelberg University
- Start
- Aug 2018
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib, cytarabine and gemtuzumab ozogamicin in acute myeloid leukemia (AML), sponsored by Heidelberg University. Started Aug 2018; status: completed.
02
Drugs
bortezomibcytarabinegemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2017-005158-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-005158-12.